Alvotech and UK-based Advanz Pharma have broadened their commercial collaboration with an agreement to include three additional biosimilar candidates for commercialisation in Europe.
The agreement encompasses the supply and commercialisation of biosimilar candidates to Novartis’ human antibody interleukin-1β blocker, Ilaris (canakinumab), the cluster of differentiation 20 (CD20)-directed cytolytic antibody Kesimpta (ofatumumab), and a third undisclosed biosimilar candidate.
Go deeper with GlobalData
Ilaris and Kesimpta are intended for inflammatory diseases and relapsing forms of multiple sclerosis respectively.
Alvotech will manage the development and commercial supply of these biosimilars, while Advanz Pharma will oversee their registration and commercialisation within the region.
The agreement encompasses development and commercial milestones for the products, which could amount to up to $180m.
Additionally, they will engage in a revenue-sharing arrangement.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAdvanz Pharma CEO Steffen Wagner stated: “By adding canakinumab, ofatumumab and another early-stage programme to our strategic partnership with Alvotech, Advanz Pharma now holds European commercial rights to proposed biosimilars referencing more than ten originator biologics.
“Importantly, two of these three new candidates address rare-disease indications, reinforcing our commitment to broaden access to rare disease and speciality medicines.”
Alvotech CEO and chairman Róbert Wessman stated: “We are very pleased to expand our partnership with Advanz Pharma. We now have agreed to launch proposed biosimilars to more than ten reference products in Europe, starting in 2025 and reaching beyond 2030.”
This collaboration builds upon their previous agreements in 2023, which covered proposed biosimilars to several other treatments
The supply and commercialisation agreements under this partnership extend to all 30 European Economic Area member nations, along with Switzerland and the UK.
For the biosimilar candidate to Novartis’ Xolair (omalizumab), the agreement includes Australia, New Zealand and Canada.
In November 2024, the European Medicines Agency (EMA) accepted a marketing authorisation application for AVT05, Alvotech and Advanz Pharma’s proposed biosimilar to Johnson & Johnson’s (J&J) Simponi (golimumab).
